Cargando…
MED19 encodes two unique protein isoforms that confer prostate cancer growth under low androgen through distinct gene expression programs
MED19, a component of the mediator complex and a co-regulator of the androgen receptor (AR), is pivotal in prostate cancer cell proliferation. MED19 has two isoforms: a full-length “canonical” and a shorter “alternative” variant. Specific antibodies were developed to investigate these isoforms. Both...
Autores principales: | Ruoff, Rachel, Weber, Hannah, Wang, Ying, Huang, Hongying, Shapiro, Ellen, Fenyö, David, Garabedian, Michael J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600210/ https://www.ncbi.nlm.nih.gov/pubmed/37880276 http://dx.doi.org/10.1038/s41598-023-45199-9 |
Ejemplares similares
-
MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen
por: Weber, Hannah, et al.
Publicado: (2021) -
Phosphorylation of the Androgen Receptor by PIM1 in Hormone Refractory Prostate Cancer
por: Ha, Susan, et al.
Publicado: (2012) -
Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer
por: Hillebrand, Ana Caroline, et al.
Publicado: (2018) -
WNT5A Encodes Two Isoforms with Distinct Functions in Cancers
por: Bauer, Matthieu, et al.
Publicado: (2013) -
Androgen-dependent alternative mRNA isoform expression in prostate cancer cells
por: Munkley, Jennifer, et al.
Publicado: (2018)